Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Device Enables Early Detection of Cancerous Skin Tumors

By LabMedica International staff writers
Posted on 29 Dec 2009
Israeli researchers are developing a new device that detects cancerous skin tumors, including melanomas that are not visible to the naked eye.

During initial testing by scientist from Ben-Gurion University of the Negev (Be'er Sheva, Israel), the optical spectro-polarimetric imaging (OSPI) instrument revealed new textures of lesions that have never been seen before--including melanoma in patients who were diagnosed with various skin lesions and were awaiting surgery for their removal. More...
The instrument diagnosed 73 types of lesions, some of them cancerous.

Dermatologists and plastic surgeons typically diagnose skin tumors by their appearance with the naked eye and only rarely using a dermatoscope--a magnifying tool that allows tumors to be examined in detail. The OSPI biosensor utilizes safe, infrared wavelengths and LC devices to measure tumor characteristics, including contours and spread.

"This is an exciting preliminary development since the initial testing shows that we can now identify microscopic tumors in the biological layers of the skin,” explained Prof. Abdulahim, who is head of the BGU Electro-Optical Unit in the faculty of engineering sciences and is leading the research group. "As we continue to develop the OSPI, we also see an opportunity to use this technology for detecting other types of cancerous growths.”

Cancerous mole detection is typically performed by looking for one or more characteristic visible symptoms: if the mole is asymmetrical; if its outline is blurred or irregular; if it has multiple colors; if it is larger than 5 mm in diameter; and if stands up above the skin.

According to the American Cancer Society (Atlanta, GA, USA), more than one million cases of skin cancer are diagnosed yearly in the United States. Melanoma, the most serious type of skin cancer, will account for approximately 8,650 of the 11,590 deaths due to skin cancer in 2009.

Israel has also seen a rise in skin cancer cases in recent years. According to the Health Ministry, 1 of every 39 men and 1 of every 50 women in Israel will be affected with melanoma in their lifetime.

Related Links:
Ben-Gurion University of the Negev


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.